Page last updated: 2024-08-18

pyridostigmine bromide and Neoplasms

pyridostigmine bromide has been researched along with Neoplasms in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (50.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J	1
Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L	1
Johansson, S; Lundh, H; Nilsson, O; Rosén, I	1
Claussen, GC; Head, TC; Kim, DS; Oh, SJ	1

Reviews

1 review(s) available for pyridostigmine bromide and Neoplasms

Article	Year
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nature cell biology, 2015, Volume: 17, Issue:11 Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction	2015

Article

Year

6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.

Nature cell biology, 2015, Volume: 17, Issue:11

Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction

2015

Trials

1 trial(s) available for pyridostigmine bromide and Neoplasms

Article	Year
Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle & nerve, 1997, Volume: 20, Issue:9 Topics: Adult; Aged; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophysiology; Female; Guanidine; Guanidines; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Neoplasms; Pyridostigmine Bromide; Time Factors; Treatment Outcome	1997

Article

Year

Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome.

Muscle & nerve, 1997, Volume: 20, Issue:9

Topics: Adult; Aged; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophysiology; Female; Guanidine; Guanidines; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Neoplasms; Pyridostigmine Bromide; Time Factors; Treatment Outcome

1997

Other Studies

2 other study(ies) available for pyridostigmine bromide and Neoplasms

Article	Year
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells	2007
Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta neurologica Scandinavica, 1993, Volume: 88, Issue:2 Topics: 4-Aminopyridine; Amifampridine; Clinical Protocols; Drug Synergism; Drug Therapy, Combination; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscles; Neoplasms; Parasympathomimetics; Pyridostigmine Bromide	1993